OIS@AAO 2015
IOPtima CEO Ronan Castro gives OISTV an update on the company’s commerical launch of the IOPtimate system in Europe and Asia, including operations in China…
Read MoreJay Duker, MD, Director of the New England Eye Center and Chairman of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine,…
Read MoreThis video honors Tom Frinzi and Dan Durrie, MD, for their successful leadership at WaveTec. Recipients: Tom Frinzi Thomas Frinzi is Senior Vice President of…
Read MoreModerator: Casey McGlynn J. Casey McGlynn formed the Life Sciences Group at Wilson Sonsini Goodrich & Rosati in 1990. It is a nationally recognized practice…
Read MorePresenter: Jonathan Norris Jon Norris is a Managing Director with SVB Healthcare team, responsible for new business development. View Full Profile
Read MorePresenter: Joseph Gilliam Mr. Gilliam has over 16 year’s experience in strategic advisory services, private and public equity and debt financings. Prior to J.P. Morgan,…
Read MorePresenter: Emmett T. Cunningham Jr., MD, PhD, MPH Dr. Cunningham joined Clarus Ventures with 20+ years in the biomedical and biopharmaceutical sectors. Prior, Dr. Cunningham…
Read MoreAllegro Ophthalmics describes itself as a “mid-stage biotech company.” Its lead agent, Luminate, is an integrin peptide therapy that is the subject of a number…
Read MoreCEO Mark Shearman, MD, PhD, describes Applied Genetic Technologies Corp., known as AGTC, as a clinical-stage biotechnology company focused on developing its proprietary gene vector…
Read MoreVision Medicines is working on developing two agents for the treatment of ocular diseases: VM100 for treatment of geographic atrophy and intermediate age-related macular degeneration…
Read MoreDavid P. Southwell, president and CEO of Inotek Pharmaceuticals, spelled out the focus of his clinical-stage biopharmaceutical firm in no uncertain terms at OIS@AAO. “Inotek…
Read MoreEleven Biotherapeutics is using its proprietary AMP-Rx protein-engineering platform to develop agents for more effective treatment of allergic conjunctivitis as well as to investigate new…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")